After the anti-covid drug, the Defence Research and Development Organisation (DRDO) is now working to solve the oxygen problem of patients.
The PM Care Fund has reportedly given the green signal to the oxycare system developed by the DRDO. Its supply process may start soon. DRDO on Wednesday informed in this regard.
Significantly, the organization’s Covid Drug 2-deoxy-D-glucose (2-DG) has recently received emergency use from the Drug Controller General of India. According to media reports, the PM Cares Fund has allowed the purchase of 150,000 units of the DRDO-developed oxycare system. It is said to be worth around Rs 322.5 crore. According to the report, it is a SpO2-based oxygen supply system that controls oxygen, which delivers oxygen to the patient based on the SpO2 levels felt.
The deal will buy 1 lakh manual and 50,000 automatic oxycare systems with NRBM masks. A statement issued by the DRDO said that the oxycare system delivers supplementary oxygen based on SpO2 level and protects the patient from hypoxia. DRDO said the system was developed by the Bengaluru-based Defence Bio-Engineering and Electro Medical Laboratory (DEBEL) for high altitude jawans. It is reported that this system is designed to complete campaigns on the field and is extremely strong.
Report by Chetali S M
Reported on – 12/05/2021
“I love the way South India film industry not touching hearts but also crushing the charts”-Armaan Malik
Mumbai’s, Rajawadi hospital treats a newborn and his sister with rare disease
PM Modi to address UN General Assembly on his visit to US